Kura Oncology (KURA) Profit After Tax (2010 - 2026)

Kura Oncology (KURA) has 17 years of Profit After Tax data on file, last reported at -$74.7 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 30.62% year-over-year to -$74.7 million in Q1 2026; TTM through Mar 2026 was -$296.1 million, a 64.43% decrease from a year earlier, with the FY2025 full-year figure at -$278.7 million, down 60.17% from the prior year.
• Profit After Tax for Q1 2026 stood at -$74.7 million, up from -$81.2 million in the prior quarter.
• Over the last five years, Profit After Tax for KURA reached as high as -$19.2 million in Q4 2024 and fell as low as -$81.2 million in Q4 2025.
• Historically, Profit After Tax has averaged -$47.3 million across 5 years, with a median of -$42.8 million in 2023.
• Across the five-year window, Profit After Tax jumped 55.09% in 2024 and plunged 322.3% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$25.5 million in 2022, then slumped by 67.87% to -$42.8 million in 2023, then soared by 55.09% to -$19.2 million in 2024, then slumped by 322.3% to -$81.2 million in 2025, then gained by 7.91% to -$74.7 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$74.7 million in Q1 2026, -$81.2 million in Q4 2025, and -$74.1 million in Q3 2025.